Renfu Pharmaceutical Group has been approved to establish a national-level postdoctoral research workstation.

Release time:

2024-05-28 15:53

Source:

Recently, following review and recommendation by the competent authorities at the provincial, municipal, and district levels, and upon approval and filing by the Office of the National Postdoctoral Administration Committee, Renfu Pharmaceutical Group Co., Ltd. has officially established a postdoctoral research workstation and will proceed with the recruitment and training of postdoctoral fellows as planned.

Postdoctoral researchers are an important component of the nation’s strategic talent pool. Enterprise-based postdoctoral research workstations, approved by the Ministry of Human Resources and Social Security and the National Postdoctoral Administration Committee, serve as a key platform in China for attracting, cultivating, and utilizing high-level young talents. They play a vital role in promoting the deep integration of industry, academia, and research, as well as in driving enterprise innovation and scientific and technological progress.

As a leading enterprise in Hubei Province’s pharmaceutical industry, Renfu Pharmaceutical has always adhered to the principle that “talent is the primary resource for enterprise development and innovation,” and is committed to building a team of professionals who are specialized, internationally oriented, and young. The successful establishment of this research station not only represents full recognition and trust in Renfu Pharmaceutical’s R&D innovation capabilities and its ability to independently attract and cultivate talent, but also provides a powerful lever for the company to continuously attract high-end talent, accelerate the cultivation and development of new productive forces, and further promote the commercialization of scientific and technological achievements.

Next, the company will leverage its national-level postdoctoral research workstation to deepen exchanges and cooperation with universities, research institutions, and other organizations that host postdoctoral programs. It will continue to strengthen its talent development efforts in terms of institutional framework building, resource allocation, and service support, thereby boosting high-quality development in the pharmaceutical industry.

Renfu Pharmaceutical Group’s Postdoctoral Research Station Approved

Yichang Renfu Pharmaceutical’s oxycodone hydrochloride extended-release tablets have been approved for a new 10mg dosage strength.

Sanxia Pudong has been recognized as a Single-Item Champion Enterprise in Hubei Province’s manufacturing sector.

Trending News

Accelerating the layout for independent production of innovative drugs: The construction of Renfu Pharmaceutical’s innovative drug industrial base has begun.

Yichang Renfu Pharmaceutical’s Bupropion Hydrochloride Extended-Release Tablets (XL) Approved for Marketing in Canada

Yichang Renfu Pharmaceutical has been selected as an Excellence-Level Smart Factory for 2025.

Yichang Renfu Pharmaceutical won second and third prizes in the finals of the China Innovation Methods Competition.

Deng Renjie Conducts a Survey of Renfu Pharmaceutical

Tide of Innovation and Entrepreneurship, Pursuing Dreams Together | The 22nd Corporate Day of China Merchants Group and the 2025 Employee Badminton and Basketball Tournament of Renfu Pharmaceutical Were Successfully Held.

Corporate culture

Make drug launches safer and faster, and ensure the tree of life remains evergreen.